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Abstract
Introduction: Lupus nephritis (LN) is a major complication of systemic lupus erythematosus. NLRP3 inflammasome
activation, reactive oxygen species (ROS) and mononuclear leukocyte infiltration in the kidney have been shown to
provoke the acceleration and deterioration of LN, such as accelerated and severe LN (ASLN). Development of a novel
therapeutic remedy based on these molecular events to prevent the progression of the disease is clinically warranted.
Methods: Citral (3,7-dimethyl-2,6-octadienal), a major active compound in a Chinese herbal medicine Litsea cubeba, was
used to test its renoprotective effects in a lipopolysaccharide (LPS)-induced mouse ASLN model by examining NLRP3
inflammasome activation, ROS and COX-2 production as well as Nrf2 activation. The analysis of mechanisms of action of
Citral also involved its effects on IL-1β secretion and signaling pathways of NLRP3 inflammasome in LPS-primed
peritoneal macrophages or J774A macrophages.
Results: Attenuated proteinuria, renal function impairment, and renal histopathology, the latter including intrinsic
cell proliferation, cellular crescents, neutrophil influx, fibrinoid necrosis in the glomerulus, and peri-glomerular
infiltration of mononuclear leukocytes as well as glomerulonephritis activity score were observed in Citral-treated
ASLN mice. In addition, Citral inhibited NLRP3 inflammasome activation and levels of ROS, NAD(P)H oxidase subunit
p47phox, or COX-2, and it enhanced the activation of nuclear factor E2-related factor 2 (Nrf2). In LPS-primed
macrophages, Citral reduced ATP-induced IL-1β secretion and caspase-1 activation, but did not affect LPS-induced
NLRP3 protein expression.
Conclusion: Our data show that Citral alleviates the mouse ASLN model by inhibition of the activation signal, but not
the priming signal, of NLRP3 inflammasome and enhanced activation of Nrf2 antioxidant signaling.
Introduction
Lupus nephritis (LN), a disease characterized by immune
complex-mediated renal inflammation and fibrosis, is clas-
sified into six classes according to the severity of renal
histopathology [1], as transformation from a lower grade to
a higher grade occurs [2, 3]. Acute induction of cellular
autoimmunity [4–6] and/or humoral autoimmunity [6, 7]
has been implicated in the development of the resultant
severe renal conditions, although the exact pathogenic
mechanisms remain to be determined. Importantly, ex-
pression of proinflammatory cytokines, including interleu-
kin (IL)-1β [8–10] and IL-18 [9, 11], is upregulated in
animal models of accelerated and severe LN (ASLN).
The NLR family, pyrin domain containing 3 (NLRP3)
inflammasome is known to control the activation of
caspase-1, which cleaves pro-IL-1β and pro-IL-18 to
form mature IL-1β and IL-18 [12, 13]. A priming signal
from pathogen-associated molecular patterns and an acti-
vation signal, e.g., ATP from damaged cells, are both
required for full activation of the NLRP3 inflammasome
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[12–14]. Immune complexes can trigger the activation of
the NLRP3 inflammasome in macrophages from systemic
lupus erythematosus (SLE) patients and animal models,
leading to cell and tissue damage [9, 15, 16]. We [9] and
others [10, 16] have shown that increased production of
IL-1β resulting from NLRP3 inflammasome activation and
T cell activation occurs in mouse models of LN, suggest-
ing the NLRP3 inflammasome and its downstream path-
way as an important mechanism underlying the evolution
of LN.
In addition, oxidative stress can potentiate inflammatory
processes by activating NF-κB, thereby stimulating pro-
duction of pro-inflammatory cytokines [17–19] and has
been implicated in the progression/deterioration of LN in
patients, leading to the development of severe renal condi-
tions [17, 18, 20]. The nuclear factor E2-related factor 2
(Nrf2) antioxidant signaling pathway confers protection
against oxidative stress and prevents cell and tissue injury
[17, 21, 22], and deletion of the Nrf2 gene results in a
lupus-like autoimmune nephritis in mice [22, 23]. Disrup-
tion of the Nrf2 gene has been shown to result in
increased production of IL-1β, TNF-α, and IL-6 in mice
[24–26]. Recently, we showed that expression of Nrf2 and
its downstream molecules, heme oxygenase-1 and gluta-
thione peroxidase, is reduced in mouse models of diabetic
nephropathy, IgA nephropathy, and ASLN, and that these
changes can be prevented by treatment with Chinese
herbal medicine-derived pure components with Nrf2-
mediated anti-oxidant activity [14, 27, 28]. In addition,
reactive oxygen species (ROS) can cause NLRP3 inflam-
masome activation [14, 29], and both oxidative stress and
inflammation have been shown to be involved in the
development of LN [18, 30] and its progression and
deterioration [17, 27].
Citral (3,7-dimethyl-2,6-octadienal), a major active com-
pound found in Litsea cubeba, a traditional Chinese herbal
medicine, can inhibit activation of macrophages and
NF-κB and the production of pro-inflammatory cyto-
kines, including IL-1β [31] and also shows potent antioxi-
dant activity [32, 33]. In a recent study, we demonstrated
that the renoprotective effect of Citral results from activa-
tion of the Nrf2 antioxidant pathway and inhibition of NF-
κB activation in the early stage of adriamycin-induced focal
segmental glomerulosclerosis in mice [34] (patented by
Taiwan, I463979 and USA, 8,993,637). However, whether
Citral has an effect on the accelerated and progressive
stage of immune complex-mediated glomerular disorders,
such as ASLN, remains to be determined. In this study, we
tested the hypothesis that Citral can attenuate an ASLN
model in mice and examined the modes of action of its
renoprotective effect. We clearly show that by inhibiting
the activation signal of NLRP3 inflammasome and increas-
ing Nrf2 anti-oxidative activity, Citral effectively prevented
the development of ASLN.
Methods
Preparation of Citral (3, 7-dimethyl-2-7-octadienal)
Citral was isolated from fruits of L. cubeba, a trad-
itional Chinese herbal medicine as described previously
(purity ≥96 %) [34].
Mouse ASLN model and experimental protocol
A mouse ASLN model was used in which female NZB/
Wf1 mice (8 weeks old) were injected intraperitoneally
with either saline or 0.8 μg/g body weight of lipopolysac-
charide (LPS) (Sigma-Aldrich, St. Louis, MO, USA) in
saline twice weekly for 5 weeks as described previously
[27]. Starting 2 days before LPS/saline injection, Citral
(200 mg/kg of body weight) or vehicle (corn oil) was
administered daily by gavage throughout the study. The
mice were sacrificed at the end of week 5 after the start
of disease induction. All animal experiments were per-
formed with the approval of the Institutional Animal
Care and Use Committee of The National Defense Medical
Center, Taiwan, and were conducted in accordance with
national guidelines.
Clinical and pathological evaluation
Urine samples were collected in metabolic cages for 6 h
at the end of each week, and urinary albumin and cre-
atinine (Cr) were measured as described previously [35].
Serum samples were collected at the end of each week
to measure levels of blood urea nitrogen (BUN) and Cr
as described previously [35]. At the end of the study,
renal pathology and scoring of glomerular proliferation,
fibrinoid necrosis, neutrophil infiltration, crescent forma-
tion, and peri-glomerular inflammation was performed on
50 randomly sampled glomeruli [9], and a glomeruloneph-
ritis activity score (range 0–24) was calculated as described
previously [36].
Immunofluorescence, immunohistochemistry, and terminal
deoxynucleotidyl transferase dUTP nick end labeling
(TUNEL)
Frozen sections of renal tissues were stained with fluores-
cein isothiocyanate (FITC)-conjugated antibodies against
IgG or C3 (Cappel Lab. Inc., Cochranville, PA, USA) as de-
scribed previously [37] and semiquantitative analysis of the
total immunofluorescence intensity performed as described
previously [38]. Formalin-fixed and paraffin-embedded
renal sections were incubated with antibodies against CD3
(pan-T cell), or F4/80 (monocytes/macrophages) (both
from Serotec, Kidlington, UK), followed by biotinylated
second antibodies, and avidin-biotin-peroxidase complex
(both from Dako Denmark A/S, Glostrup, Denmark) as
described previously [28].
The TUNEL assay was used to detect apoptosis in
renal sections using an ApopTag Plus Peroxidase in Situ
Apoptosis Detection kit (Chemicon International, Inc.,
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Billerica, MA, USA) according to the manufacturer’s
instructions. Numbers of CD3-, F4/80-, or TUNEL-
positive cells were determined using PAX-it software as
described previously [28].
Serum levels of autoantibody
Serum anti-dsDNA antibodies were measured using an
anti-dsDNA ELISA kit (Alpha Diagnostic, TX, USA) ac-
cording to the manufacturer’s instructions. The absorbance
at 450 nm was measured using an ELISA plate reader
(Bio-Tek, Winooski, VT, USA).
Flow cytometry
Isolated splenocytes were double-stained with FITC-
conjugated antibodies against mouse CD3 (pan-T cells),
CD4, CD8 (T cell subsets), or CD19 (B cell marker) and
phycoerythrin (PE)-conjugated anti-mouse CD69 anti-
bodies (H1.2 F3; marker of activated T and B cells)
(BD Biosciences, San Diego, CA, USA) and analyzed
on a FACSCalibur (BD Biosciences) as described pre-
viously [37].
For intracellular staining of IFN-γ or IL-4, splenocytes
were cultured for 5 h in 24-well microtiter plates in the
presence or absence of phorbol myristate acetate, ionomy-
cin, and monensin (all from Sigma-Aldrich). They were
then stained for 30 minutes on ice with FITC-conjugated
anti-mouse CD3 antibodies (BD Biosciences), fixed in 1 %
paraformaldehyde (Sigma-Aldrich), and re-suspended in
permeabilization buffer, as described previously [37], then
intracellular cytokines was stained for 30 minutes on ice
with PE-conjugated antibodies against IFN-γ or IL-4 (BD
Biosciences), followed by flow cytometric analysis using a
FACSCalibur (BD Biosciences).
Renal levels of ROS
Renal ROS levels were estimated using a chemolumi-
nescence assay for superoxide anion, the results being
presented as reactive luminescence units (RLU) per 15 mi-
nutes per milligram dry weight (i.e., RLU/15 min/mg dry
weight) as described previously [9].
Renal activities of NF-κB and cytoplasmic caspase-1 activity
and serum levels of IL-1β and prostaglandin E2 (PGE2)
Renal cytoplasmic and nuclear proteins were extracted
using a nuclear extract kit (Active Motif, Carlsbad, CA,
USA) according to the manufacturer’s instructions.
Nuclear NF-κB p65 activation was quantified using an
ELISA-based TransAM NF-κB kit (Active Motif) accord-
ing to the manufacturer’s protocol. Caspase-1 activity in
the cytoplasmic fraction was measured using caspase-1 ac-
tivity kits (R&D Systems, Minneapolis, MN, USA) accord-
ing to the manufacturer’s instructions, and is presented as
a value relative to the protein concentration. Serum levels
of IL-1β or PGE2 were measured using commercial ELISA
kits (both from R&D Systems), according to the manufac-
turer’s instructions.
Western blots to estimate levels of nuclear Nrf2 and
cytosolic NAD(P)H oxidase subunit p47phox,
cyclooxygenase-2 (COX-2), NLRP3, and IL-1β in the kidney
Cytoplasmic and nuclear proteins extracted from renal
tissues as described above were used for Western blot
analysis using antibodies against Nrf2, p47phox, COX-2,
or IL-1β (all from Santa Cruz Biotechnology, Santa Cruz,
CA, USA) or NLRP3 (Enzo Life Sciences Inc, Farmingdale,
NY, USA). Antibodies against Lamin A (nuclear proteins)
or β-actin (cytosolic proteins), both from Santa Cruz, were
used as internal controls.
In vitro studies
Effect of Citral on LPS/ATP-induced IL-1β secretion by primary
peritoneal macrophages
Peritoneal macrophages, elicited by an intraperitoneal
(IP) injection in 8-week-old female NZB/Wf1 mice with
4 % sterile thioglycollate medium as described previously
[14], were harvested and grown in RPMI 1640 medium
supplemented with 2 mML-glutamine, 100 U/ml of peni-
cillin, 100 μg/ml of streptomycin, 2.5 μg/ml of amphoteri-
cin B, and 10 % heat-inactivated fetal calf serum (all from
Gibco, Grand Island, NY, USA) at 37 °C in a 5 % CO2
incubator. The cells (2.5 × 106 in 500 μl of medium) were
incubated for 30 minutes with Citral or saline, then LPS
(Sigma-Aldrich; final concentration 1 μg/ml) was added
for 5.5 h. The cells were then incubated for 30 minutes
with addition of ATP (Sigma-Aldrich; 5 mM) for 30 mi-
nutes, then IL-1β levels in the culture medium were mea-
sured using an ELISA kit (R&D Systems), according to the
manufacturer’s instructions.
Effect of Citral on NLRP3 inflammasome activation in a
macrophage cell line
The murine macrophage cell line J774A.1 was purchased
from the American Type Culture Collection (Rockville,
MD, USA). The cells (2 × 106 in 2 ml of medium) were
(1) incubated for 30 minutes with or without Citral, then
LPS (final concentration 1 μg/ml) or saline was added
for 5.5 h, and incubated for 30 minutes with 5 mM ATP
or saline, or (2) incubated for 5.5 h with LPS (1 μg/ml)
or saline and the cells were washed with saline, then Citral
or saline was added for 30 minutes, followed by addition of
5 mM ATP or saline for 30 minutes. In both assays, IL-1β
levels in the culture medium were then measured using an
ELISA kit (R&D Systems), while levels of NLRP3, activated
caspase-1 (p10), or pro-caspase-1 (p45) in the cells were
measured by western blotting, as described previously [28].
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Data analysis
For animal experiments, the results are presented as the
mean ± standard error of the mean (SEM) and compari-
sons between two groups were performed using Student’s
t test except in the case of differences in urinary albumin/
Cr ratios, which were examined using one-way analysis of
variance (ANOVA). For experiments using cultured mac-
rophages, all values are given as the mean ± SD, and data
Fig. 1 Effects of Citral on clinical, pathological features and renal lesions in mouse model. a Time-course of changes in the urine albumin/creatinine ratio.
b Serum blood urea nitrogen (BUN) levels; c serum creatinine (Cr) levels. d-f Kidney histopathological evaluation by H&E staining; g-k percentage of
glomeruli affected by the indicated parameter. l Scoring of glomerulonephritis activity. Original magnification × 400. Bars show mean ± standard error of
the mean for 7 mice per group; *p <0.05, **p <0.01, ***p <0.005, #not detectable. ALSN accelerated and severe lupus nephritis
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analysis was performed using one-way ANOVA with sub-
sequent Scheffé test. A p value <0.05 was considered
statistically significant.
Results
Citral improves albuminuria and renal function
A progressive type of mouse ASLN model was used in
which female NZB/Wf1 mice (8 weeks old) were injected
IP with LPS twice weekly for 5 weeks, and starting 2 days
before LPS injection were given Citral or vehicle daily by
gavage until the end of the study. As shown in Fig. 1a,
vehicle + ASLN mice developed albuminuria which began
at the end of week 2 and increased up to the end of the
study. However, in Citral-treated ASLN (Citral + ASLN)
mice, this effect was markedly inhibited. Similarly, im-
proved renal function was seen at the end of week 5 in
Citral + ASLN mice compared to vehicle + ASLN mice as
demonstrated by serum levels of BUN (Fig. 1b) and Cr
(Fig. 1c) (both p <0.05).
Citral prevents severe renal injury and moderates
systemic T cell activation
Light microscopy showed that compared to normal con-
trol mice (Fig. 1d), vehicle + ASLN mice had severe renal
pathological lesions, including intrinsic cell proliferation
(Fig. 1e, g), cellular crescents (Fig. 1e, h), neutrophil influx
(Fig. 1e, i), fibrinoid necrosis (Fig. 1e, j) in the glomerulus,
and peri-glomerular infiltration of mononuclear leuko-
cytes (Fig. 1e, k). Again, the severity of these renal lesions
was markedly reduced in Citral + ASLN mice (all p <0.01)
(Fig. 1f, g-k), although they still had very mild renal patho-
logical changes. We also calculated a histopathology score,
the glomerulonephritis activity score [36], developed to
determine glomerulonephritis activity for the assessment
of LN in humans, and found that this was markedly
increased in vehicle + ASLN mice compared to normal
controls and significantly lower in Citral + ASLN mice
(Fig. 1l). In addition, as shown in Fig. 2, apoptosis was
frequently seen in the kidneys of vehicle + ASLN mice and
was significantly decreased in the glomeruli and renal
tubules of Citral + ASLN mice, in which there were only a
few apoptotic figures.
Immunofluorescence studies demonstrated marked
deposits of IgG and C3 in the glomeruli of vehicle +
ASLN mice compared to normal control mice (total
intensity score 204 ± 18 vs. 31 ± 8, p <0.005), which were
still present in the glomeruli of the Citral + ASLN mice
(total intensity score 211 ± 23). Although significantly
increased serum levels of anti-dsDNA antibody were
seen in vehicle + ASLN (1.6 ± 0.2 optical density (OD)
vs. 0.6 ± 0.1 OD, p <0.01) and Citral + ASLN (1.4 ± 0.3
OD vs. 0.6 ± 0.1 OD, p <0.01) mice compared to normal
control mice, there was no significant difference in serum
levels of the autoantibody between vehicle + ASLN and
Fig. 2 Effects of Citral on renal apoptosis in a mouse model. a-c Apoptosis in the kidney detected by terminal deoxynucleotidyl transferase-mediated
dUTP nick-end labeling (TUNEL). d-e Scoring of apoptotic cells in the glomerulus as cell number/glomerular cut section (gcs) (d) or in the tubules as cell
number per field (e). Original magnification × 400. Bars show mean ± standard error of the mean for 7 mice per group; ***p <0.005, #not detectable. ALSN
accelerated and severe lupus nephritis
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Citral + ASLN mice. The results obtained from both
experiments suggest that Citral did not have inhibitory
effects on humoral immune response in the mice at the
dose used throughout the study.
Flow cytometric analysis of spleen cells showed that
activation of CD3+ T cells (Fig. 3a), CD4+ T cells
(Fig. 3b), and CD8+ T cells (Fig. 3c), as shown by the
percentage of such cells expressing the activation marker
CD69, was significantly increased in vehicle + ASLN mice
compared to normal controls, and this effect was again
markedly inhibited in Citral + ASLN mice (Fig. 3a-c). In
contrast, although activation (CD69 positivity) of B cells
(CD19+ cells) was significantly increased in vehicle +
ASLN mice compared to normal controls, there was no
significant difference between the vehicle + ASLN and
Citral + ASLN mice (Fig. 3d). The percentage of total T
cells (CD3+ cells) expressing IFN-γ (Fig. 3e) or IL-4
(Fig. 3f) was greatly increased in vehicle + ASLN mice
compared to normal controls, and this effect was mark-
edly inhibited in Citral + ASLN mice.
Citral inhibits NLRP3 inflammasome activation
As activation of the NLRP3 inflammasome in macro-
phages has been shown to be involved in the progression
of spontaneous SLE in NZB/Wf1 mice [9], we performed
several experiments to examine the mechanism of action
of Citral in ASLN mice and in vitro cultures.
Animal model
Significant renal infiltration of T cells (CD3+) was seen
at the end of week 5 in vehicle + ASLN mice compared
to normal control mice and this effect was markedly
inhibited in Citral + ASLN mice (Fig. 4a-c, g, h). In
addition, in vehicle + ASLN mice there was significant
infiltration of macrophages (F4/80+) into the kidney and
this effect was also significantly decreased in Citral +
ASLN mice (Fig. 4d-f, i, j). Renal nuclear NF-κB p65 ac-
tivity was also significantly increased in vehicle + ASLN
mice compared to normal controls and was also signifi-
cantly inhibited in Citral + ASLN mice (Fig. 4k).
Western blotting showed increased NLRP3 expression
in the kidneys of vehicle + ASLN mice compared to nor-
mal control mice (p <0.01) and this effect was prevented
by Citral treatment (p <0.005) (Fig. 5a, b). Vehicle +
ASLN mice also expressed significantly higher renal IL-
1β levels (Fig. 5a, c) and renal caspase-1 activity than
normal control mice (Fig. 5d) and Citral administration
resulted in a significant reduction in both (both p <0.01).
In addition, significantly increased serum levels of IL-1β
were observed in vehicle + ASLN mice, compared to
Fig. 3 Effects of Citral on systemic T cell and B cell activation and intracellular staining of T lymphocytes from the spleen for IFN-γ or IL-4 in a mouse
model. a-d Percentage of systemic CD3+ T cells (a), CD4+ T cells (b), CD8+ T cells (c), or CD19+ B cells (d) expressing the activation marker CD69. e and
f Percentage of spleen CD3+ T cells expressing IFN-γ+ (e) or IL-4+ (f). Bars show mean ± standard error of the mean for 7 mice per group; *p <0.05,
***p <0.005, ns not significant. ALSN accelerated and severe lupus nephritis
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normal control mice (86.2 ± 15.0 pg/ml vs. 46.3 ±
8.5 pg/ml; p <0.05), and Citral administration resulted
in decreased serum levels of IL-1β, although there was
no statistical significance (86.2 ± 15.0 pg/ml vs. 61.8 ±
9.2 pg/ml; p = 0.06).
In vitro studies of the effect of Citral on LPS + ATP-induced
IL-1β secretion by naïve peritoneal macrophage cultures or
the mouse macrophage cell line
Full activation of the NLRP3 inflammasome requires
both a priming signal (e.g., LPS) and an activation signal
Fig. 4 Effects of Citral on renal infiltration by monocytes/macrophages and T cells and NF-κB activation in the kidney of a mouse model. Detection of
CD3+ T cells (a-c) and F4/80+ monocytes/macrophages (d-f) by immunohistochemistry. Original magnification × 400. Arrows indicate positively stained
cells. Scoring of CD3+ cells (g and h) or F4/80+ cells (i and j) in the glomerulus (g and i) or interstitium (h and j). k Nuclear NF-κBp65 activity. Bars show
mean ± standard error of the mean for 7 mice per group; ***p <0.005, ns not significant. ALSN accelerated and severe lupus nephritis
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(e.g., ATP) [14, 39]. In the first study, peritoneal macro-
phages from untreated 8-week-old female NZB/Wf1
mice were incubated in vitro for 30 minutes with Citral
or saline, followed by addition of LPS for 5.5 h, then
were incubated with ATP for 30 minutes, when IL-1β
levels in the culture medium were measured by ELISA;
controls were cells incubated at each stage with saline.
The results showed that Citral completely blocked
LPS + ATP-induced IL-1β production (Fig. 5e).
In the second study, we examined the effect of Citral
on each step of LPS/ATP-induced NLRP3 inflamma-
some activation in the mouse macrophage cell line
J774A.1. In the first experiment, control J774A.1 macro-
phages were left untreated, while others were incubated
with or without different concentrations of Citral for
30 minutes before addition of LPS for 5.5 h, and incuba-
tion with ATP for 30 minutes, then IL-1β secretion was
measured by ELISA and caspase-1 generation by western
blotting. The results showed that Citral significantly
inhibited IL-1β secretion in a dose-dependent manner
(Fig. 6a), but did not affect the generation of active
caspase-1 (Fig. 6b). In the second experiment, we incu-
bated the cells with LPS for 5.5 h, washed with saline,
before addition of vehicle or different concentrations of
Citral for 30 minutes, followed by ATP stimulation for
30 minutes, and found that Citral inhibited both IL-1β
secretion (Fig. 6c) and caspase-1 activation (Fig. 6d) in a
dose-dependent manner. These results demonstrate that
Citral inhibits the production and secretion of IL-1β
through activation of the NLRP3 inflammasome. We
also tested its ability to inhibit expression of both
NLRP3 and pro-IL-1β (IL-1β precursor) proteins in
LPS-activated J774A.1 cells by incubating the cells with
different concentrations of Citral for 30 minutes before
addition of LPS for another 6 h, and found that Citral had
no effect on LPS-induced NLRP3 expression (Fig. 6e, f ),
but inhibited LPS-induced pro-IL-1β expression in a
dose-dependent manner (Fig. 6e, g).
Citral inhibits the increase in ROS, NAD(P)H oxidase
subunit p47phox, COX-2, or PGE2 levels, and it enhances
nuclear Nrf2 levels
Citral has been shown to be an antioxidant in inflamma-
tory diseases [14, 40] and inhibits LPS-induced ROS pro-
duction in macrophages [34, 40]. As shown in Fig. 7a,
renal levels of superoxide anion were significantly in-
creased in vehicle + ASLN mice compared to normal con-
trols (p <0.01) and this effect was significantly inhibited in
Fig. 5 Effect of Citral on NLRP3 inflammasome activation in the kidney of the animal model, and on in vitro lipopolysaccharide (LPS) + ATP-induced IL-1β
secretion by naïve peritoneal macrophages. a Representative western blots for cytosolic levels of NLRP3 and IL-1β in the kidney, with β-actin as the loading
control. b and c Semiquantitative analysis of the NLRP3/β-actin ratio and IL-1β/β-actin ratio. d Cytosolic caspase-1 activity measured by ELISA
and expressed relative to the protein content. e Effect of Citral pretreatment of peritoneal macrophages from naïve mice on in vitro LPS +
ATP-induced IL-1β secretion. Peritoneal macrophages were incubated with Citral or saline for 30 minutes, then LPS was added for 5.5 h, when
the cells were incubated for 30 minutes with ATP. The controls were incubated with saline at each stage. Bars show mean ± standard error of
the mean for 7 mice per group; **p <0.01, ***p <0.005. ALSN accelerated and severe lupus nephritis
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Citral + ASLN mice (p <0.05). Renal cytosolic p47phox
levels in vehicle + ASLN mice were also greatly increased
compared to normal control mice (p <0.01), and this effect
was significantly decreased by Citral treatment (p <0.05) to
levels similar to those in normal control mice (Fig. 7b, c).
Next, we measured renal cytosolic COX-2 levels and
serum levels of PGE2, a downstream molecule of COX-2,
and found that renal COX-2 levels (Fig. 7b, d) and serum
PGE2 levels (Fig. 7e) were significantly increased in
vehicle + ASLN mice compared to normal control mice
(both p <0.01), and both effects were significantly
inhibited in Citral + ASLN mice (both p <0.05). We
then evaluated nuclear levels of Nrf2 in renal tissues, as
this transcription factor triggers an antioxidant pathway
in renal inflammation and fibrosis [27, 28]. As shown
in Fig. 7f and g, vehicle + ASLN mice had significantly
lower nuclear levels of Nrf2 than normal control mice
(p <0.05) and this effect was significantly decreased in
Citral + ASLN mice (p <0.05).
Discussion
In the present study, as persistent inflammatory episodes
and oxidative stress are implicated in both the develop-
ment and progression/deterioration of LN [20, 27], we
examined whether Citral could alleviate the clinical
manifestations and pathological changes in an ASLN
model in NZB/Wf1 mice. Our results showed that Citral
inhibited the development of ASLN, as demonstrated by
reduced albuminuria, improved renal function, and im-
proved renal histopathology in intrinsic cell proliferation,
cellular crescents, neutrophil influx, fibrinoid necrosis in
the glomerulus, and peri-glomerular infiltration of mono-
nuclear leukocytes, and the glomerulonephritis activity
score. Mechanistic studies showed that inhibition of the
activation signal of NLRP3 inflammasome and enhanced
activation of Nrf2 antioxidant signaling were involved in
the major mechanisms of action for the renoprotective
effects of Citral.
Bachiega et al. (2011) [31] demonstrated that Citral
reduces LPS-induced IL-1β secretion in macrophages.
We further examined the inhibitory effect of Citral on
NLRP3 inflammasome activation was verified by naïve
peritoneal macrophages from untreated mice incubated
with Citral or saline, then tested for LPS/ATP-induced
IL-1β secretion (Fig. 5e). Citral significantly reduced
both IL-1β secretion (Fig. 6c) and caspase-1 activation
(Fig. 6d) when added to cultures of J774A.1 macro-
phages after LPS priming, but before ATP stimulation,
suggesting that it reduces IL-1β secretion by inhibiting
ATP-mediated caspase-1 activation. In addition, addition
of Citral before LPS priming also caused reduced IL-1β
secretion (Fig. 6a), but did not reduce caspase-1 activation
(Fig. 6b). Although Citral did not affect NLRP3 expression
in LPS-activated macrophages (Fig. 6e, f ), it reduced LPS-
Fig. 6 In vitro effect of Citral on NLRP3 inflammasome activation in J774A.1 macrophages. a IL-1β secretion by lipolysachharide (LPS) +
ATP-activated macrophages. b Western blots showing caspase-1 activation in LPS + ATP-activated macrophages. c ATP-induced IL-1β secretion
by LPS-primed macrophages. d ATP-induced caspase-1 activation in LPS-primed macrophages. e Representative western blots showing the effect of
treatment with different concentrations of Citral for 30 minutes before addition of LPS for 6 h on NLRP3 and pro-IL-1β levels in J774A.1 macrophages. f
and g Semiquantitative analysis of the NLRP3/β-actin ratio (f) and pro-IL-1β/β-actin ratio (g). The data are expressed as the mean ± SD for three separate
experiments; the histogram shows the quantification expressed as the mean± SD; *p <0.05, **p <0.01, ns not significant
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induced pro-IL-1β expression (Fig. 6e, g). We therefore
infer that the Citral-mediated decrease in IL-1β secretion
in LPS-primed macrophages involves downregulation of
pro-IL-1β production. Collectively, our in vitro data indi-
cate that Citral inhibits IL-1β secretion through: (1) redu-
cing IL-1β precursor (pro-IL-1β) protein expression
(Fig. 6e) and (2) inhibiting ATP-induced caspase-1 activity
(Fig. 6d). These results indicate that Citral inhibits both
LPS-mediated pro-IL-1β expression and ATP-mediated
activation signal of NLRP3 inflammasome.
Interestingly, the fact that Citral administration in vivo
resulted in reduced renal NLRP3 expression in Citral-
treated mice (Citral + ASLN mice) suggests that other
molecular pathways may be involved in the mechanism
of action of Citral in this mouse model of ASLN. In this
regard, for instance, binding of IL-1β to IL-1 receptors
Fig. 7 Effect of Citral on renal levels of superoxide anion, cytoplasmic NAD(P)H oxidase subunit p47phox and cyclooxygenase-2 (COX-2), nuclear nuclear
factor E2-related factor 2 (Nrf2), and serum prostaglandin E2 (PGE2) in mouse model. a Reactive oxygen species levels in renal tissues expressed as
reactive luminescence units (RLU)/15 min/mg dry weight. b Representative western blots for cytosolic levels of p47phox and COX-2, with β-actin as the
loading control. c and d Semiquantitative analysis of the p47phox/β-actin ratio (c) and the COX-2/β-actin ratio (d). e Serum PGE2 levels measured by
ELISA. f Representative western blots for nuclear levels of Nrf2. with Lamin A as the loading control. g Semiquantitative analysis of the Nrf2/
Lamin A ratio. Bars show mean ± standard error of the mean for 7 mice per group; *p <0.05, **p <0.01, and ***p <0.005. ASLN accelerated and
severe lupus nephritis
Ka et al. Arthritis Research & Therapy  (2015) 17:331 Page 10 of 13
was found to promote production of COX-2 [41]. In our
recent report, COX-2 promotes NLPR3 activation and
IL-1β protein secretion [39]. In the present study, we
demonstrated that reduced renal COX-2 levels were
seen in Citral + ASLN mice compared to vehicle + ASLN
mice (Fig. 7b, d). The data suggest the COX-2-mediated
activation of NLRP3 inflammasome may be one of attrib-
uted pathways responsible for the renoprotective effects of
Citral. It should be noted, however, that to determine
whether the NLRP3 inflammasome-associated molecules
and related signaling pathways are crucial in the mecha-
nisms of Citral for its renoprotective effects, the ASLN
model should be used in mice deficient in each of the sev-
eral molecules or with neutralizing antibodies, and all
these tests deserve further investigation. Another issue is
whether the effect of Citral is specific for the NLRP3-
inflammasome-mediated IL-1β production. Other inflam-
masomes, such as AIM2 and NLRC4 inflammasomes,
deserve further evaluation of the renoprotective effects of
the compound.
Finally, Citral prevented kidney inflammation and
resultant fibrosis n this severe LN model by inhibiting
the systemic immune response. Abnormal systemic
function of T and B cells in innate and adaptive immune
responses is involved in the canonical pathophysiological
pathways underlying the development and progression
of LN [4, 6]. In the present study, although we failed to
show any inhibitory effects of Citral on B cell activation
or on immune deposits in the kidneys, Citral administra-
tion markedly inhibited CD4+ T cell activation (Fig. 3b)
and the production of IFN-γ by these cells (Fig. 3e). Im-
portantly, T helper (Th)1 cells can promote the activation
of macrophages by producing IFN-γ, and macrophages
are involved in NLRP3 inflammasome activation, which
may provide IL-1β signaling to activate T cells [42, 43].
The beneficial effect of Citral administration in this severe
LN model may involve an effect on Th cell responses. This
potential mode of action of Citral in its renoprotective
effects is worth further investigation.
Blockade of ROS production in studies involving the
use of chemical scavengers of ROS, pharmacological
inhibitors of NAD(P)H oxidase, or siRNA-mediated
knockdown of p22phox NAD(P)H oxidase has been shown
to inhibit NLRP3 inflammasome activation in response to
a wide range of stimuli [14, 44]. Our previous study
showed that inflammasome activation is mediated by ROS
by using ROS inhibitors [45] Taken together, we infer that
reduced ROS generation by Citral may explain the result-
ant decreased pro-IL-1β protein levels by the compound.
Furthermore, we showed that increased ROS production
was seen in the kidney in ASLN mice and that Citral acti-
vated Nrf2 in ASLN mice, supporting the ideas that oxida-
tive stress contributes to the pathogenesis of ASLN and
that enhanced activation of the Nrf2 antioxidant pathway
prevents the renal damage associated with severe LN.
NLRP3 expression is tightly controlled by the activity of
multiple signaling receptors, and activation of NF-κB
results in activation of the NLRP3 inflammasome and
resultant IL-1β production [46]. In the present study, we
showed that increased production of ROS (Fig. 7a) and in-
creased NF-κB activation (Fig. 4k) were seen in the kidney
of vehicle + ASLN mice and these effects were signifi-
cantly inhibited by Citral. This finding is in agreement
with our previous report that Citral administration can
markedly inhibit NF-κB p65 activation in the kidney cor-
tex in a renal inflammation and fibrosis model in mice
[34]. Furthermore, renal NLRP3 levels in vehicle + ASLN
mice were increased and renal posttranslational process-
ing of caspase-1 and IL-1β promoted, all suggestive of
NLRP3 inflammasome activation, and these effects were
inhibited in Citral + ASLN mice (Fig. 5). However, a
decrease of NLRP3 levels and IL-1β and increases in Nrf2
levels in kidneys after Citral treatment compared to
vehicle treatment (Figs. 5a and 7g), which may result from
the reduced recruitment of macrophages into the kidney
after treatment, but this may be part of the mechanisms
involved in these proteins in the protective effects of
Citral. A selective Nrf2 agonist, bardoxolone, has been
found to enhance the magnitude of proteinuria in a rat
model of diabetic nephropathy [47], but was found to be
beneficial in the prevention and therapy of tissue injury in
an animal model of cancer [48, 49]. Further studies are
needed to resolve these conflicting results and determine
the mechanistic pathways involved.
Conclusion
Citral alleviates the mouse ASLN model by inhibition of
the activation signal of NLRP3 inflammasome and
enhanced activation of Nrf2 antioxidant signaling.
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